NYSEARCA:PRME Prime Medicine - PRME Price, Holdings, & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $12.28 -0.25 (-2.00%) (As of 03/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$12.16▼$12.6750-Day Range$11.21▼$21.1152-Week Range$11.07▼$21.73Volume134,379 shsAverage Volume166,618 shsMarket Capitalization$1.16 billionAssets Under Management$1.03 millionDividend YieldN/ANet Expense Ratio0.95% ProfileChartInstitutional OwnershipHeadlines About Prime Medicine (NYSEARCA:PRME)Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.Read More Receive PRME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address PRME ETF News HeadlinesMarch 27, 2023 | finance.yahoo.comPrime Medicine to Present at Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease DaysMarch 9, 2023 | finance.yahoo.comPrime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 31, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!January 9, 2023 | finance.yahoo.comPrime Medicine Announces Recent Progress and Highlights 2023 Strategic PrioritiesJanuary 3, 2023 | finance.yahoo.comPrime Medicine to Present at 41st Annual J.P. Morgan Healthcare ConferenceDecember 15, 2022 | apnews.comPress Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularisNovember 19, 2022 | cnbc.com'Compelling' and 'attractive': These stocks are firing on all cylinders, JPMorgan saysNovember 15, 2022 | cnbc.comThis gene-editing company that went public last month could rally 20%, Jefferies saysMarch 31, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.November 10, 2022 | reuters.comPrime Medicine IncSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PRME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerFirst Trust Fund NameFirst Trust Heitman Global Prime Real Estate ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:PRME Inception Date11/12/2015 Fund ManagerJerry Ehlinger, John White, Jacques Perdrix, Andreas Welter Webwww.primemedicine.com PhoneN/AFund Focus Asset ClassReal Estate BenchmarkN/A CategoryReal Estate FocusReal Estate Development LevelBlended Development RegionGlobal Number of Holdings0 Fund Statistics Assets Under Management$1.03 million Average Daily Volume$213.00 Discount/Premium3.91% Administrator, Advisor and Custodian AdministratorBrown Brothers Harriman & Co. AdvisorFirst Trust Advisors L.P. CustodianBrown Brothers Harriman & Co. DistributorFirst Trust Portfolios L.P. Transfer AgentBrown Brothers Harriman & Co. TrusteeN/A Lead Market MakerCredit Suisse Miscellaneous Outstanding Shares94,336,000BetaN/A Prime Medicine ExpensesTypePRMEReal Estate ETFsReal Estate ETFsNYSEARCA ETFsAll ETFsManagement Fee0.95%0.45%0.44%0.49%0.49%Other Expenses0.00%0.19%0.22%0.58%0.55%Total Expense0.95%0.50%0.50%0.70%0.68%Fee Waiver0.00%-0.20%-0.19%-0.63%-0.57%Net Expense0.95%0.47%0.47%0.56%0.56% Prime Medicine (PRME)Full Holdings Details Key ExecutivesDr. Keith Michael Gottesdiener M.D. (Age 69)Pres, CEO, Sec. & Director Comp: $867.11kDr. Ann L. Lee Ph.D. (Age 61)Chief Technical Officer Comp: $171.19kDr. Jeremy S. Duffield M.D. (Age 55)Ph.D., Chief Scientific Officer Comp: $994.4kDr. Andrew Anzalone M.D. (Age 37)Ph.D., Co-Founder, Sr. Scientist II, Head of Prime Editing Platform & Head of Platform Devel. Dr. David R. Liu Ph.D.Co-Founder & Chair of Scientific Advisory BoardMs. Carman Alenson CPA (Age 58)M.B.A., Chief Accounting Officer & Interim CFO Dr. Meredith Goldwasser (Age 52)Sr. VP of Strategy & Corp. Operations and Head of Strategy & Corp. Operations Dr. Karen Brown J.D.Ph.D., Sr. VP of Intellectual Property & Legal AffairsMs. Niamh AlixChief HR OfficerMr. Richard Brudnick (Age 65)Chief Bus. Officer More ExecutivesSimilar ETFsUBS ETRACS Monthly Pay 2xLeveraged MSCI US REIT Index ETNNYSEARCA:LRETGlobal X MSCI China Real Estate ETFNYSEARCA:CHIRALPS REIT Dividend Dogs ETFNYSEARCA:RDOGIQ CBRE NextGen Real Estate ETFNYSEARCA:ROOFHoya Capital Housing ETFNYSEARCA:HOMZInsiders & InstitutionsMetLife Investment Management LLCBought 6,091 shares on 3/23/2023Ownership: 0.006%Point72 Middle East FZEBought 37,609 shares on 2/16/2023Ownership: 0.040%Morgan StanleyBought 20,389 shares on 2/15/2023Ownership: 0.022%Sandia Investment Management LPBought 10,000 shares on 2/15/2023Ownership: 0.011%MetLife Investment Management LLCBought 6,091 shares on 2/15/2023Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions PRME ETF - Frequently Asked Questions Should I buy or sell Prime Medicine stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prime Medicine in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRME shares. View PRME analyst ratings or view top-rated stocks. What is Prime Medicine's stock price forecast for 2023? 4 equities research analysts have issued 1 year price objectives for Prime Medicine's stock. Their PRME share price forecasts range from $21.00 to $27.00. On average, they expect the company's share price to reach $23.75 in the next year. This suggests a possible upside of 93.4% from the stock's current price. View analysts price targets for PRME or view top-rated stocks among Wall Street analysts. How have PRME shares performed in 2023? Prime Medicine's stock was trading at $18.58 at the beginning of the year. Since then, PRME stock has decreased by 33.9% and is now trading at $12.28. View the best growth stocks for 2023 here. What does PRME invest in? Prime Medicine is a real estate fund issued by First Trust. PRME focuses on real estate investments. The fund's investments total to approximately $1.03 million assets under management. What is the management fee for Prime Medicine? Prime Medicine's management fee is 0.95% and has no other recorded expenses or fee waivers. The net expense ratio for PRME is 0.95%. What is Prime Medicine's stock symbol? Prime Medicine trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "PRME." When does the company's lock-up period expire? Prime Medicine's lock-up period expires on Tuesday, April 18th. Prime Medicine had issued 10,294,118 shares in its IPO on October 20th. The total size of the offering was $175,000,006 based on an initial share price of $17.00. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted. Who are Prime Medicine's major shareholders? Prime Medicine's stock is owned by a variety of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (2.52%), ARK Investment Management LLC (1.74%), EcoR1 Capital LLC (0.64%), Moore Capital Management LP (0.53%), Sumitomo Mitsui Trust Holdings Inc. (0.52%) and Nikko Asset Management Americas Inc. (0.52%). Insiders that own company stock include 2019 Gp LLC Gv and Thomas Cahill. View institutional ownership trends. How do I buy shares of Prime Medicine? Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Prime Medicine's stock price today? One share of PRME stock can currently be purchased for approximately $12.28. How much money does Prime Medicine make? Prime Medicine (NYSEARCA:PRME) has a market capitalization of $1.16 billion. This page (NYSEARCA:PRME) was last updated on 3/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.